Browsing by Author "Areola Emmanuel Damilare"

Now showing 1 - 4 of 4
  • Item
    Anti-depressant Potentials of Some Bioactive Components of Basella alba Leaves in Chronic Unpredictable Stress Rat Model
    (Nigerian Journal of Neuroscience, 2023-03-20) Jimoh-Abdulghaffaar Hidaayah O.; Areola Emmanuel Damilare; Jimoh Olanrewaju; Sodimu Ayobami; Adebosin Victor; Bakare Azeez; Ipinmoroti Deborah; Olagbemi Oluwafisolami; Yousuph Sarah; Egwa Jessica; Ojulari Lekan
    Bioactive components of Basella alba leaves are responsible for their antidepressant-like activity. However, the com ponent with the greatest anti-depressant activity is unknown. This study investigated the antidepressant-like activities of the bioactive components (phenols, flavonoids, and glycosides) in Basella alba leaves. Forty-two male Wistar rats weighing 50–200 g were randomly divided into six groups (n=7). All the groups, except for the control, were subjected to chronic unpredictable stress (CUS) for five weeks. The rats in the CUS groups were treated with normal saline (1 mL/kg), escitalopram (5 mg/kg), and each of the phenol-, flavonoid-, and glycoside-rich Basella alba extracts (200 mg/kg) orally for twenty-one days. The tail suspension, sucrose preference, light-dark box, and hole-board tests were carried out before and after the induction of depression. In the CUS groups, reduced mobility time on tail suspension, increased percentage sucrose consumption, frequency of head dips on the hole board, and line-cross frequency in the light-dark box were observed. The latency on the hole board was reduced with Basella alba components, while there was a significant (p<0.05) decrease in serum brain-derived neurotrophic factor and an increase in serum IL-6 in the CUS animals not treated with extracts. The phenol-rich Basella alba extract showed the most potent antidepressant like activity, followed by the flavonoid-rich extract. The bioactive components of Basella alba, particularly phenols, were effective in ameliorating the depressive features of CUS and should be further studied for use as an adjunct or stand alone antidepressant.
  • Item
    Anti-depressant Potentials of Some Bioactive Components of Basella alba Leaves in Chronic Unpredictable Stress Rat Model
    (Nigerian Journal of Neuroscience, 2023-04-20) Jimoh-Abdulghaffaar Hidaayah Oluwamayowa; Areola Emmanuel Damilare; Jimoh Olanrewaju Saheed; Sodimu Ayobami Tobi; Adebosin Victor Tope; Bakare Azeez Olawale; Ipinmoroti Deborah Ifeoluwa; Olagbemi Oluwafisolami; Yousuph Sarah Olanike; Egwa Jessica Okache; Ojulari Lekan Sheriff
    Bioactive components of Basella alba leaves are responsible for their antidepressant-like activity. However, the component with the greatest anti-depressant activity is unknown. This study investigated the antidepressant-like activities of the bioactive components (phenols, flavonoids, and glycosides) in Basella alba leaves. Forty-two male Wistar rats weighing 50–200 g were randomly divided into six groups (n=7). All the groups, except for the control, were subjected to chronic unpredictable stress (CUS) for five weeks. The rats in the CUS groups were treated with normal saline (1 mL/kg), escitalopram (5 mg/kg), and each of the phenol-, flavonoid-, and glycoside-rich Basella alba extracts (200 mg/kg) orally for twenty-one days. The tail suspension, sucrose preference, light-dark box, and hole-board tests were carried out before and after the induction of depression. In the CUS groups, reduced mobility time on tail suspension, increased percentage sucrose consumption, frequency of head dips on the hole board, and line-cross frequency in the light-dark box were observed. The latency on the hole board was reduced with Basella alba components, while there was a significant (p<0.05) decrease in serum brain-derived neurotrophic factor and an increase in serum IL-6 in the CUS animals not treated with extracts. The phenol-rich Basella alba extract showed the most potent antidepressantlike activity, followed by the flavonoid-rich extract. The bioactive components of Basella alba, particularly phenols, were effective in ameliorating the depressive features of CUS and should be further studied for use as an adjunct or standalone antidepressant.
  • Item
    Anti-inflammatory and antithrombotic effects of nicotine exposure in oral contraceptive-induced insulin resistance is glucocorticoid-independent
    (Pharmacological Reports, 2016-12-16) Olatunji Lawrence Aderemi; Michael Olugbenga Samuel; Adeyanju Oluwaseun Aremu; Areola Emmanuel Damilare; Soladoye Ayodele Olufemi
    Background: Reports showed that estrogen-progestin oral contraceptive (COC) or tobacco smoking causes increased risk of cardiovascular diseases (CVD) in premenopausal women. Studies also suggest that nicotine; a major tobacco alkaloid may worsen or improve atherothrombotic CVD. Altered hemorheology, prothrombotic and pro-inflammatory biomarkers, have been implicated in the development of atherothrombotic CVD events. However, the effect of non-smoking nicotine exposure on these biomarkers during COC treatment is not yet established. We therefore sought to determine the effects of nicotine exposure during COC treatment on these biomarkers, and also tested the hypothesis that the nicotine effects would be glucocorticoid-dependent. Methods: Female Sprague-Dawley rats aged 10 weeks were given (po) vehicle, low-dose nicotine (0.1 mg/kg) or high-dose nicotine (1.0 mg/kg) with or without COC steroids (5.0 µg/kg ethinylestradiol and 25.0 µg/kg levonorgestrel) daily for 6 weeks. Results: COC treatment or nicotine exposure led to increased insulin resistance (IR), hemorheological (blood viscosity, hematocrit and plasma viscosity), prothrombotic (plasminogen activator inhibitor-1), pro-inflammatory (uric acid, C-reactive protein, neutrophil/lymphocyte and platelet/lymphocyte ratios) biomarkers and corticosterone. However, these effects except that on corticosterone were abrogated by nicotine exposure during COC treatment. Conclusions: Our study indicates that nicotine- or COC-induced IR may be mediated via inflammatory/thrombotic pathway. The results imply that nicotine exposure could impact negatively on atherothrombotic biomarkers in COC non-users, whereas the impact in COC users could be positive. The results also suggest that the anti-inflammatory, antithrombotic and blood viscosity-lowering effects of nicotine exposure during COC use is circulating glucocorticoid-independent.
  • Item
    Inhibition of adenosine deaminase and xanthine oxidase by valproic acid abates hepatic triglyceride accumulation independent of corticosteroids in female rats treated with estrogen-progestin
    (Canadian Journal Publishing, 2018-07-12) Omolekulo Tolulope Eniola; Areola Emmanuel Damilare; Olufunto Olayinka Badmus; Badmus Olayinka Olufunto; Michael Olugbenga Samuel; Kim Inkyeom; Olatunji Lawrence Aderemi
    Elevated circulating uric acid has been postulated to play an important pathophysiological role in estrogen-progestin combined oral contraceptive (COC)-induced hypertension and endothelial dysfunction. We hypothesized that disruption of glucoregulation and liver triglyceride (TG) accumulation induced by COC use would be abated by valproic acid (VPA) treatment through suppression of adenosine deaminase (ADA) and xanthine oxidase (XO) activities. Female Wistar rats aged 9-10 weeks were treated with a combination of estrogen-progestin COC steroids (1.0 μg ethinylestradiol and 5.0 μg levonorgestrel; p.o.) with or without VPA (100.0 mg/kg; p.o.) daily for 6 weeks. The result shows that the disrupted glucoregulation and associated elevated hepatic ADA activity, plasma and hepatic XO activity, uric acid (UA), TG/HDL-cholesterol, total cholesterol, and malondialdehyde induced by COC treatment were attenuated by VPA treatment. However, VPA did not have any effect on plasma aldosterone, corticosterone, ADA, circulating and hepatic free fatty acid. Our results demonstrate that suppression of plasma and hepatic XO activities, along with hepatic ADA activity and UA by VPA treatment, protects against disrupted glucoregulation and increased liver TG by COC independent of elevated corticosteroids. The findings imply that VPA would provide protection against the development of cardiometabolic disorder via inhibition of the ADA/XO/UA-mediated pathway.